daunorubicin has been researched along with arabinofuranosyluracil in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (66.67) | 18.7374 |
| 1990's | 1 (33.33) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Rustum, YM | 1 |
| Büchner, T; Hiddemann, W; Kewer, U; Reuter, C; Rolf, C; Schleyer, E; Uhrmeister, C; Unterhalt, M; Wörmann, B; Zühlsdorf, M | 1 |
| Bauch, HJ; Pielken, HJ; Preusser, P | 1 |
3 other study(ies) available for daunorubicin and arabinofuranosyluracil
| Article | Year |
|---|---|
Multiple determinants of antimetabolite action in humans.
Topics: Animals; Antimetabolites, Antineoplastic; Arabinofuranosylcytosine Triphosphate; Arabinofuranosyluracil; Cytarabine; Daunorubicin; Deamination; DNA; Doxorubicin; Drug Resistance; Humans; Leukemia, Myeloid, Acute; Neoplasms, Experimental | 1979 |
Differences in the intracellular pharmacokinetics of cytosine arabinoside (AraC) between circulating leukemic blasts and normal mononuclear blood cells.
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Arabinofuranosylcytosine Triphosphate; Arabinofuranosyluracil; Cytarabine; Daunorubicin; Drug Administration Schedule; Humans; Leukemia, Myeloid; Leukocytes, Mononuclear; Lymphoma, Non-Hodgkin; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Thioguanine | 1992 |
Pharmacokinetic study of cytosine arabinoside in patients with acute myelogeneous leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arabinofuranosyluracil; Cytarabine; Daunorubicin; Humans; Kinetics; Leukemia, Myeloid, Acute; Mitoxantrone; Thioguanine | 1987 |